Health
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment – MD Linx
MDLinx original journal summary on Lung Cancer, Oncology from Lung Cancer
Researchers assessed efficacy of osimertinib-based combination therapies in non-small cell lung cancer (NSCLC) patients harbouring
T790M mutations who developed progressive disease following treatment with osimertinib. Participants were NSCLC patients…
Continue Reading
-
General16 hours agoChina and Philippines trade blame over latest South China Sea clash
-
General22 hours agoCalls for government to ‘get on with’ CSIRO Ginninderra Experiment Station land sale after three-year delay
-
Noosa News24 hours agoBetty’s Burgers National Burger Day
-
General16 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire